Key result
Pretreatment of cardiac fibroblasts with pioglitazone reduced anoxia-reoxygenation-induced fibroblast growth, collagen type-I synthesis, MMP-1 expression, ROS generation, and NF-kappaB activation.
Why the study?
Does pioglitazone reduce fibroblast growth and collagen synthesis in cardiac fibroblasts exposed to anoxia-reoxygenation?
Does pioglitazone reduce fibroblast growth and collagen synthesis in cardiac fibroblasts exposed to anoxia-reoxygenation?
p-value: p=< 0.05
Pioglitazone attenuates anoxia-reoxygenation-induced cardiac fibroblast growth and collagen synthesis, likely by inhibiting ROS generation and NF-kappaB activation.
Pioglitazone may limit fibroblast activation in ischemia-reperfusion; leaves open clinical translation from this animal model.
BACKGROUND: Cardiac remodeling after ischemic injury is a major cause of heart failure. In this process, fibroblast growth and collagen synthesis and degradation play a critical role. Recent studies indicate that ligands of the peroxisome proliferator-activated receptors-gamma (PPAR-gamma) alter cardiac remodeling during chronic ischemia. This study was designed to investigate if the PPAR-gamma ligand pioglitazone would modulate fibroblast growth and collagen type-I synthesis (and expression) in cardiac fibroblasts exposed to anoxia-reoxygenation (A-R). METHODS AND RESULTS: Cardiac fibroblasts were exposed to anoxia (95% N2/5% CO2) and then reoxygenation (95% air/5% CO2). A-R increased fibroblast growth (MTT assay) as well as collagen type-I synthesis (H-proline incorporation) and protein expression (Western analysis). Concurrently, there was a parallel increase in the expression of matrix metalloproteinase-1 (MMP-1) in fibroblasts. Pretreatment of cardiac fibroblasts with pioglitazone (10 M) reduced all these effects of A-R. Further, A-R stimulated intracellular reactive oxygen species (ROS) generation and activated the redox-sensitive transcription factor NF-kappaB (both P < 0.05). Both these phenomena were inhibited by pretreatment of cells with pioglitazone. CONCLUSION: Thus, it appears that A-R stimulates fibroblast cell growth, collagen type-I synthesis, and MMP-1 expression in cardiac fibroblasts, most likely a result of ROS generation. Inhibition of ROS generation and induction of NF-kappaB in cardiac fibroblasts during A-R may be a mechanism of action of pioglitazone.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2004) studied Cardiac remodeling after ischemic injury (in vitro model). Pioglitazone vs. Anoxia-reoxygenation without pioglitazone was evaluated on Fibroblast growth, collagen type-I synthesis, MMP-1 expression, ROS generation, and NF-kappaB activation (p=< 0.05). Pretreatment of cardiac fibroblasts with pioglitazone reduced anoxia-reoxygenation-induced fibroblast growth, collagen type-I synthesis, MMP-1 expression, ROS generation, and NF-kappaB activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: